Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($2.23), $0.16 worse than the analyst estimate of ($2.07). Revenue for the quarter came in at $98.1 million versus the consensus estimate of $109.79 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Lowered to $25 at H.C. Wainwright
• Morgan Stanley Downgrades Ultragenyx Pharma (RARE) to Equalweight
• Dell’s earning report was bullish for Intel CPU demand, analyst says